Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations

OBJECTIVES: To compare the cost-effectiveness of first-line gefitinib, erlotinib, afatinib, and osimertinib in patients with non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations. METHODS: A systematic review and network meta-analysis (NMA) were conducted to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Health Econ
Main Authors: Holleman, Marscha S., Al, Maiwenn J., Zaim, Remziye, Groen, Harry J. M., Uyl-de Groot, Carin A.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2019
Assuntos:
Original Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7058671/
https://ncbi.nlm.nih.gov/pubmed/31541309
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10198-019-01117-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados